Doxycycline and OA Progression
Osteoarthritis

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis (OA), Knee, Doxycycline, Skeletal disorder, Placebo, Urinalysis, NSAIDs, Joint space narrowing (JSN), WOMAC
Eligibility Criteria
Inclusion Criteria: Women 45-64 years of age. Upper tertile of sex-, age- and race-adjusted norms for body mass index. Unilateral knee OA at baseline. Postmenopausal status or otherwise incapable of childbearing. Ability to ambulate (move about) independently without assistive devices. Ability to read and write in English or Spanish and give informed consent. Exclusion Criteria: Premenopausal status (unless subject has had a hysterectomy). Current use of any investigational drug. Significant hematologic, renal, hepatic or cardiovascular disease (but not including mild/moderate hypertension) or any other serious medical condition that might preclude the subject's ability to participate fully in the project, keep clinic appointments, etc. Prior surgery (including arthroscopy) of the contralateral knee. Significantly abnormal laboratory values at the time of enrollment. Pigmented villonodular synovitis of the knee. Synovial chondromatosis. Charcot arthropathy. A known "secondary" cause of OA, including acute or chronic infectious OA; crystal-induced arthritis; systemic inflammatory connective tissue disease (e.g., rheumatoid arthritis, systemic lupus erythematosus); osteonecrosis; Paget's disease; or metabolic diseases, such as hemochromatosis, Wilson's disease, or ochronosis. Chondrocalcinosis, however, will not be an exclusion criterion. Conditions other than knee OA which limit lower extremity function and mobility and/or would confound the evaluation of knee pain and function (e.g., clinically significant spinal or hip arthritis, painful or dysfunctional feet, peripheral vascular disease, lumbar radiculopathy, stroke, etc.). Steroid injection into either knee within past 3 months. A history of photosensitivity (sensitivity to light) or any other adverse reaction to a tetracycline. Failure to pass a "faintness-of-heart" test (pre-randomization compliance test). Prior chronic use of tetracycline (e.g., for severe acne). Severe OA (Kellgren and Lawrence Grade IV) of the index knee. Salicylate use, with a mean dose >2g/d. Institutionalization.
Sites / Locations
- University of Alabama at Birmingham
- University of Arizona Arthritis Center
- Northwestern University Medical Center
- Indiana University Medical Center
- Arthritis Research Center Foundation
- University of Pittsburgh Medical Center